Health Canada Grants Apricus Biosciences Pre-NDS Meeting for Femprox for Female Sexual Arousal Disorder

SAN DIEGO, May 7, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Health Canada has granted the Company's request for a Pre-New Drug Submission ("Pre-NDS") meeting to obtain regulatory guidance from the agency for Femprox®, its topical alprostadil cream for the treatment of female sexual arousal disorder ("FSAD"). The meeting is scheduled to take place on July 17, 2012. Apricus Bio expects to obtain feedback from Health Canada regarding the suitability of their existing clinical, preclinical, and chemistry data to support a New Drug Submission ("NDS") in Canada.

Back to news